Research & Projects

ESCMID Panorama

ESCMID Pipeline Corner

ESCMID offers small innovative pharmaceutical companies with early-stage antimicrobial therapies in development a platform at ECCMID to present their products to a wider audience.

Antimicrobial drug pipeline talks at ECCMID 2017 in Vienna!

ECCMID provided small innovative companies with a platform to give an overview of their R&D pipelines and present recent advances in their early-stage programmes to a wider audience.

Sunday, 23 April 2017

12:30 – 14:00, Foyer E


12:30 – 13:20 Pipeline talks

13:20 – 13:30 Experience report 

13:30 – 14:00 Discussion, networking

ePosters are accessible via the congress app and on dedicated terminals until the end of the congress on 25 April.

Presenting companies

•    AiCuris GmbH, Germany (ePoster only)
•    Allecra Therapeutics GmbH, Germany
•    Arsanis Biosciences, Austria/United States
•    Cantab Anti-infectives Ltd, United Kingdom
•    Centauri Therapeutics Ltd, United Kingdom (ePoster only)
•    Naicons Srl., Italy
•    NovaBiotics Ltd, United Kingdom
•    Phico Therapeutics Ltd, United Kingdom
•    Scynexis Inc., United States (ePoster only)
•    Septeos, France (ePoster only)
•    Synthetic Biologics Inc., United States
•    TAXIS Pharmaceuticals Inc., United States

Experience report of Redx Pharma, United Kingdom, with Carb-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a private-public initiative that invests in companies and research teams with antimicrobial products in development.

Pipeline talks at ECCMID 2016 in Amsterdam

After successful initiation of the Pipeline Corner and the Pipeline Talks at ECCMID 2015 in Copenhagen, the ECCMID Programme Committee extend the new format at ECCMID 2016 in Amsterdam.

The dedicated session took place at ECCMID 2016 in Amsterdam on Sunday, 10 April 2016, 13:00 - 14:00

Presenting companies:

  • BioVersys, Switzerland
  • Melinta, United States
  • Deutsches Zentrum für Infektionsforschung, Germany
  • Discuva, United Kingdom
  • Cidara, United States
  • Spero, United States
  • ABAC Therapeutics, Spain
  • Biovertis, Germany
  • Nabriva, Austria
  • Vitas Pharma, India

download press release

Pipeline Corner at ECCMID 2015

The dedicated Pipeline Corner at ECCMID 2015 generated great interest among the research community, larger pharmaceutical companies, service providers, venture capital firms, and the press. The display of electronic posters has proved to be the starting point for promising discussions and meetings throughout the conference.

download press release

The posters can be found in our eLibrary under this link.

Get an overview on ESCMID initiatives in the field of antimicrobial resistance, find out more about EUCAST, TROCAR, GRACE, ESGAP, ESGARS, ESGNI and ECCMID. The ESCMID PK/PD of Anti-Infectives Study Group (EPASG) is supporting the Pipeline Corner and Pipeline Talks at ECCMID.

This list displays European or international initiatives active in combatting antimicrobial resistance by developing new compounds. If you would like to add a new European or international initiative or amend an existing entry, please contact the .

New Drugs for Bad Bugs

Driving reinvestment in R&D for antibiotics and advocating their responsible use

Longitude Prize

CDC Antibiotic Resistance Solutions Initiative

Joint Programme Initiative on Antimicrobial Resistance


Last update: 11 August 2015

In 2014, ESCMID organized conference on use of old antibiotics to tackle multi-drug resistant ‘Superbugs’ and confront the imminent threat of a ‘post-antibiotic age’. Delegates at an ESCMID conference in Vienna in October 2014 have identified and agreed on a number of key actions which need to be taken urgently, if old, off patent antibiotics are to be usefully and safely drafted into the battle to combat increasing levels of antimicrobial resistance by ‘superbugs’, a growing threat to life across the world.

Link to the conference website for conference material, publications and press releases